Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Inhibitors of Bacterial Protein Synthesis

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Journal of human immunity·2026

Same author

IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC).

The journal of allergy and clinical immunology. In practice·2026

Same author

Yes, we can omit TBI for ALL!

Blood advances·2026

Same author

Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation.

American journal of respiratory cell and molecular biology·2026

Same author

Fluid accumulation and outcomes in children receiving continuous kidney replacement therapy: an appraisal of the WE-ROCK registry.

Pediatric nephrology (Berlin, Germany)·2026

Same author

Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment.

Transplantation and cellular therapy·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Liposomal amphotericin B associated with severe hyperphosphatemia.

Scott M Sutherland¹, David K Hong, Jay Balagtas

¹Division of Pediatric Nephrology, Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA. suthersm@stanford.edu

The Pediatric Infectious Disease Journal

|December 29, 2007

Summary

Four patients experienced hyperphosphatemia during liposomal amphotericin B treatment for fungal infections. Symptoms resolved upon switching to amphotericin B lipid complex, suggesting a potential link in renal insufficiency.

Related Experiment Videos

Last Updated: Jul 8, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Area of Science:

Mycology
Nephrology
Pharmacology

Background:

Invasive fungal infections necessitate potent antifungal therapies.
Amphotericin B formulations, including liposomal amphotericin B (L-AMB), are crucial for treating severe mycoses.
Renal function is a critical consideration in managing patients on nephrotoxic medications.

Observation:

Four patients receiving liposomal amphotericin B (L-AMB) developed hyperphosphatemia.
The hyperphosphatemia was observed during treatment for invasive fungal infections.
These patients had mild to moderate renal insufficiency.

Findings:

Hyperphosphatemia resolved in all four patients after transitioning from L-AMB to amphotericin B lipid complex (ABLC).
This suggests a potential adverse effect of L-AMB on phosphate homeostasis.
The incidence may be higher in patients with compromised renal function.

Implications:

Clinicians should monitor phosphate levels in patients receiving L-AMB, particularly those with renal impairment.
Transitioning to ABLC may be a viable strategy to manage L-AMB-induced hyperphosphatemia.
Further research is warranted to elucidate the mechanism and prevalence of this adverse effect.